He Zhang
Research Subjects
He Zhang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Caiqin Zhang
Laboratory Animal Center, The Fourth Military Medical University 1 Division of Cancer Biology Xi'an, Shaanxi 710032
1 shared publication - Changhong Shi
Division of Cancer Biology, Laboratory Animal Center, Air Force Medical University, Xi’an, China
1 shared publication - Dengxu Tan
Division of Cancer Biology
1 shared publication Jiaze An
Department of Hepatobiliary and Pancreaticosplenic Surgery
1 shared publication- Pengpeng Wu
Division of Cancer Biology
1 shared publication - Xu Ge
Division of Cancer Biology, Laboratory Animal Center, Air Force Medical University, Xi’an, China
1 shared publication
Latest Publications
- Open Access
- 5 August 2022
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 2022 (1) , 6596702
The Application of [68Ga]‐Labeled FAPI‐04 PET/CT for Targeting and Early Detection of Pancreatic Carcinoma in Patient‐Derived Orthotopic Xenograft Models
[18F]FDG as a probe of PET/CT is a radiolabeled glucose analogue taken up by most cells, but its batch activity is limited. [68Ga]FAPI‐04 is a promising alternative based on a fibroblast activation protein‐specific inhibitor (FAPI) labeled with radiotracer FAP. Here, a series of databases suggested that FAP expression was significantly different in pancreatic cancer compared to normal tissue. The FAP‐positive fibroblasts were evaluated around the tumor cells and the stroma. A patient‐derived orthotopic xenograft (PDOX) model of pancreatic adenocarcinoma (PDAC) exhibits significantly higher quantitative uptake of [68Ga]FAPI‐04 (P < 0.05) than [18F]FDG PET/CT in various organs. Because of relatively high (T/M) ratios, the [68Ga]FAPI‐04 is excellent for B‐mode ultrasound, NIRF, and PET/CT. Thus, [68Ga]FAPI‐04 PET displayed a better tumor specificity and can be a potential application for the early detection of pancreatic cancer.
- 5 August 2022
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 2022 (1) , 6596702
Open AccessThe Application of [68Ga]‐Labeled FAPI‐04 PET/CT for Targeting and Early Detection of Pancreatic Carcinoma in Patient‐Derived Orthotopic Xenograft Models
[18F]FDG as a probe of PET/CT is a radiolabeled glucose analogue taken up by most cells, but its batch activity is limited. [68Ga]FAPI‐04 is a promising alternative based on a fibroblast activation protein‐specific inhibitor (FAPI) labeled with radiotracer FAP. Here, a series of databases suggested that FAP expression was significantly different in pancreatic cancer compared to normal tissue. The FAP‐positive fibroblasts were evaluated around the tumor cells and the stroma. A patient‐derived orthotopic xenograft (PDOX) model of pancreatic adenocarcinoma (PDAC) exhibits significantly higher quantitative uptake of [68Ga]FAPI‐04 (P < 0.05) than [18F]FDG PET/CT in various organs. Because of relatively high (T/M) ratios, the [68Ga]FAPI‐04 is excellent for B‐mode ultrasound, NIRF, and PET/CT. Thus, [68Ga]FAPI‐04 PET displayed a better tumor specificity and can be a potential application for the early detection of pancreatic cancer.